Blueprint MBA Leadership Program - Corporate / Business Development Track
Blueprint Medicines | |
United States, Massachusetts, Cambridge | |
45 Sidney Street (Show on map) | |
Dec 27, 2024 | |
Our MBA Leadership Program: Blueprint's MBA Leadership Program is a two-year rotational program with the intent to successfully develop a pipeline of future leaders across our organization through hands-on experience, continual coaching & development, and cross-functional assignments. As a participant in our MBA Leadership Program, you will spend the first 12 months of the program in your "home" track, developing deep functional expertise. You will spend the second half of the program rotating through two other functional areas at Blueprint, expanding your depth of knowledge across teams and bringing fresh perspectives with you. What will you do? The Business Development Track: We are seeking a driven and innovative MBA to join our Business Development (BD), New Product Planning (NPP) and Investor Relations (IR) teams through different rotations. This fellowship offers a unique opportunity to gain hands-on experience in a dynamic biopharmaceutical environment. As an MBA Fellow, you will work closely with our BD, NPP, and IR teams to collaborate on strategic initiatives, market analysis, due diligence and partnership opportunities that align with Blueprint Medicines' mission to alleviate human suffering with life-changing medicines. The 24 months spent in our rotational program are designed to develop a strong foundation of business acumen and Blueprint Medicines knowledge upon which the participant can develop the readiness for a position within Business Operations. What minimum qualifications do we require?
What additional qualifications will make you a stronger candidate?
Why Blueprint? At Blueprint Medicines, we achieve impactful results because of our global crew of compassionate innovators - the Blue Crew. Through authentic relationships and our collective entrepreneurial spirit and action, we are each empowered to take ownership and execute with strategic prioritization. We put trust in our people to break through norms and conventions using their individual strengths and insights, which drives our success. This is the place where the extraordinary becomes reality, and you could be part of it. Patients are waiting. Are you ready to make the leap? Equity, Diversity, Inclusion and Affirmative Action At Blueprint Medicines, we foster a culture of equity, diversity and inclusion. A proud Equal Employment Opportunity and Affirmative Action employer, we consider all qualified applicants without regard to race, color, sex, gender identity or expression, sexual orientation, age, religion, national origin, ancestry, ethnicity, disability, veteran status, genetic information, or any other characteristic protected under applicable law. We are also an E-Verify Employer. We will make reasonable accommodations, absent undue hardship, for qualified individuals with known disabilities. If you are an individual with a disability in need of an accommodation with the application or recruiting process, please reach out to TotalRewards@blueprintmedicines.com. For more information, please see our EEO-AA Policy Statement, the EEO Know Your Rights Poster, as well as our Pay Transparency Statement. Blueprint Medicines is a fully integrated, commercial-stage, global biopharmaceutical company that invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. We pursue discovery, development, and commercialization of therapies that potently and selectively target known drivers of disease, with focused investment in therapeutic areas where we can leverage our core expertise and business infrastructure to bring scale to our science. We are bringing an approved medicine to people living with systemic mastocytosis (SM) in the U.S. and Europe. Additionally, we have a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including SM and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. #LI-Hybrid #LI-AQ1 |